NEXI · Insider Trading
NEXIMMUNE INC
Every open-market purchase and sale reported by NEXI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-13 | Kristi Jones | President and CEO | Buy | +1 | +$0 |
| 2023-11-22 | Alan S. Roemer | Director | Sell | −7,825 | −$16.05K |
| 2023-07-07 | Grant Verstandig | Director | A | +44,983 deriv. | — |
| 2023-07-07 | Timothy Bertram | Director | A | +44,983 deriv. | — |
| 2023-07-07 | Zhengbin Yao | Director | A | +44,983 deriv. | — |
| 2023-07-07 | Sol J Barer | Director | A | +44,983 deriv. | — |
| 2023-07-07 | Alan S. Roemer | Director | A | +44,983 deriv. | — |
| 2023-07-07 | Paul D'Angio | Director | A | +44,983 deriv. | — |
| 2023-07-07 | Leena Gandhi | Director | A | +44,983 deriv. | — |
| 2023-04-06 | Sol J Barer | Director | MIXED | — | — |
| 2023-04-06 | Leena Gandhi | Director | MIXED | — | — |
| 2023-04-06 | Mathias Oelke | Chief Science Officer | MIXED | +81,100 deriv. | — |
| 2023-04-06 | Zhengbin Yao | Director | MIXED | — | — |
| 2023-04-06 | Paul D'Angio | Director | MIXED | — | — |
| 2023-04-06 | Alan S. Roemer | Director | MIXED | — | — |
| 2023-04-06 | John Trainer | Chief Financial Officer | MIXED | +89,100 deriv. | — |
| 2023-04-06 | Kristi Jones | President and CEO | MIXED | +300,000 deriv. | — |
| 2023-04-06 | Timothy Bertram | Director | MIXED | — | — |
| 2023-04-06 | Grant Verstandig | Director | MIXED | — | — |
| 2023-03-31 | Sol J Barer | Director | Buy | +400,000 | +$164.12K |
| 2022-11-29 | Kristi Jones | President and CEO | A | +296,700 | — |
| 2022-11-25 | John Trainer | Chief Financial Officer | A | +125,200 | — |
| 2022-11-25 | Mathias Oelke | Chief Science Officer | A | +126,100 | — |
| 2022-11-17 | Sol J Barer | Director | Buy | +200,000 | +$96.22K |
| 2022-06-15 | Paul D'Angio | Director | A | +61,678 deriv. | — |
| 2022-06-15 | Timothy Bertram | Director | A | +61,678 deriv. | — |
| 2022-06-15 | Alan S. Roemer | Director | A | +61,678 deriv. | — |
| 2022-06-15 | Grant Verstandig | Director | A | +61,678 deriv. | — |
| 2022-06-15 | Sol J Barer | Director | A | +61,678 deriv. | — |
| 2022-06-15 | Zhengbin Yao | Director | A | +61,678 deriv. | — |
| 2022-06-07 | Grant Verstandig | Director | Buy | +66,876 | +$148.30K |
| 2022-06-02 | Grant Verstandig | Director | Buy | +133,124 | +$297.56K |
| 2022-06-02 | Sol J Barer | Director | Buy | +100,000 | +$226.15K |
| 2022-05-09 | Leena Gandhi | Director | A | +80,947 deriv. | — |
| 2022-04-07 | John Trainer | Chief Financial Officer | A | +78,100 deriv. | — |
| 2022-04-07 | Kristi Jones | President and CEO | A | +456,000 deriv. | — |
| 2022-04-07 | Mathias Oelke | Chief Science Officer | A | +60,000 deriv. | — |
| 2022-04-07 | Robert Douglas Knight | Chief Medical Officer | A | +48,000 deriv. | — |
| 2022-04-07 | Jerome B Zeldis | Executive VP of Research & Dev | A | +80,100 deriv. | — |
| 2022-03-30 | Kristi Jones | President and CEO | Buy | +10,000 | +$37.40K |
| 2022-03-28 | Grant Verstandig | Director | Buy | +190,600 | +$750.27K |
| 2022-03-24 | Sol J Barer | Director | Buy | +10,000 | +$26.65K |
| 2022-03-23 | Sol J Barer | Director | Buy | +30,000 | +$72.30K |
| 2022-03-22 | Sol J Barer | Director | Buy | +30,000 | +$64.08K |
| 2022-03-21 | Sol J Barer | Director | Buy | +30,000 | +$63.21K |
| 2021-12-22 | Alan S. Roemer | Director | M | +67,657 | +$245.87K |
| 2021-12-22 | Sol J Barer | Director | M | +50,000 | +$258.50K |
| 2021-07-09 | John Trainer | Chief Financial Officer | M | +3,432 | +$17.74K |
| 2021-06-09 | John Trainer | Chief Financial Officer | M | +3,432 | +$17.74K |
| 2021-05-19 | John Trainer | Chief Financial Officer | M | +6,864 | +$35.49K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NEXI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.